The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 13, Pages 3117
Publisher
MDPI AG
Online
2021-06-23
DOI
10.3390/cancers13133117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience
- (2021) Lavinia Monaco et al. Cancers
- The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors
- (2020) Angelo Castello et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
- (2020) Selene Ottonello et al. Frontiers in Immunology
- EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy
- (2020) Arsela Prelaj et al. Clinical Lung Cancer
- Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology
- (2020) Maria Isabella Donegani et al. Medicina-Lithuania
- Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
- (2020) Romain-David Seban et al. Cancers
- Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
- (2020) Angelo Castello et al. Frontiers in Oncology
- Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
- (2020) Yuki Katayama et al. Scientific Reports
- Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
- (2019) Roberto Ferrara et al. Journal of Thoracic Oncology
- Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression
- (2019) Biagio Ricciuti et al. Clinical Lung Cancer
- Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population
- (2019) Lucio Crinò et al. ONCOLOGIST
- Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non–small-cell Lung Cancer
- (2019) Dong Guo et al. Clinical Lung Cancer
- Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
- (2019) Jingjing Liu et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
- (2019) Alama et al. Journal of Clinical Medicine
- 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns
- (2019) O. Humbert et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer
- (2019) Francesco Grossi et al. EUROPEAN JOURNAL OF CANCER
- Hyper-progressive Disease in Patients With Non–Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT
- (2019) Angelo Castello et al. JOURNAL OF NUCLEAR MEDICINE
- Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab
- (2019) Giovanni Rossi et al. JOURNAL OF NUCLEAR MEDICINE
- Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization
- (2019) Luca Filippi et al. NUCLEAR MEDICINE COMMUNICATIONS
- Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case–Control Study
- (2019) Tatsunori Kiriu et al. OncoTargets and Therapy
- Immunotherapy and the role of imaging
- (2018) Brett W. Carter et al. CANCER
- Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria
- (2018) Hongyuan Fu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
- (2018) Alona Zer et al. Clinical Lung Cancer
- The relationship between 18 F-FDG-PETCT-derived markers of tumour metabolism and systemic inflammation in patients with recurrent disease following surgery for colorectal cancer
- (2018) S. T. McSorley et al. Colorectal Disease
- Is it time to change our vision of tumor metabolism prior to immunotherapy?
- (2018) Fabio Grizzi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
- (2018) Christos Sachpekidis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
- (2018) Alessandro Russo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Sharyn I. Katz et al. Journal of Thoracic Oncology
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer
- (2018) TAKAAKI FUJII et al. ANTICANCER RESEARCH
- Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC)
- (2018) Cem Mirili et al. International Journal of Clinical Oncology
- The Relationship Between 18F-FDG Uptake on PET/CT and Markers of Systemic Inflammatory Response in Patients Undergoing Surgery for Intrahepatic Cholangiocarcinoma
- (2018) SATORU SEO et al. ANTICANCER RESEARCH
- FDG PET/CT for assessing tumour response to immunotherapy
- (2018) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma
- (2018) Kimiteru Ito et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
- (2018) Christos Sachpekidis et al. MELANOMA RESEARCH
- Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy
- (2018) Daichi Fujimoto et al. Journal of Thoracic Oncology
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Platelet–lymphocyte ratio is an independent prognostic factor in patients withALK-positive non-small-cell lung cancer
- (2017) Ying Han et al. Future Oncology
- Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: A meta-analysis
- (2017) Yukinori Takenaka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma
- (2017) Lu Wang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer:18F-FDG PET/CT Study
- (2017) Silvia Morbelli et al. JOURNAL OF NUCLEAR MEDICINE
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma
- (2017) Steve Y. Cho et al. JOURNAL OF NUCLEAR MEDICINE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined disease progression in clinical trials
- (2017) Dickran Kazandjian et al. SEMINARS IN ONCOLOGY
- Systemic immune-inflammation index for predicting prognosis of colorectal cancer
- (2017) Jian-Hui Chen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma
- (2016) Berna Akıncı Özyürek et al. Clinical Respiratory Journal
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
- (2016) Egesta Lopci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity
- (2016) Younak Choi et al. PLoS One
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients
- (2015) Ying-Jian Song et al. TUMOR BIOLOGY
- Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2015) Yu-Mu Chen et al. PLoS One
- Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
- (2014) Hiroaki Akamatsu et al. BMC CANCER
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
- (2014) B. Hu et al. CLINICAL CANCER RESEARCH
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
- (2014) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
- (2013) Graeme J.K. Guthrie et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours
- (2013) Ashvin Paramanathan et al. SURGICAL ONCOLOGY-OXFORD
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung Cancer
- (2011) Zachary D. Horne et al. JOURNAL OF SURGICAL RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started